See the DrugPatentWatch profile for Palivizumab
Is palivizumab still under patent, and what patents actually matter for “loss of patent”?
Palivizumab (brand name Synagis) has multiple layers of intellectual property (IP), including patents on the antibody itself and on related formulations/use. So “loss of patent” for palivizumab usually depends on which specific patent claim someone is relying on and whether it has expired or been invalidated—rather than a single, universally applicable date. Public sources do not provide a single, definitive expiration date for all palivizumab-related IP in the way people often expect from small-molecule drugs.
When would biosimilars (or similar products) be allowed after palivizumab’s patent expires?
For biologics like palivizumab, market entry is tied to regulatory pathways plus patent status. Even after a “core” patent expires, additional patents (for example, on manufacturing, formulation, or specific indications) can delay entry. That means biosimilar or follow-on products may face an extended timeline if any listed patents still block approval or launch in the relevant jurisdiction.
Why “patent expiry” often doesn’t immediately create cheaper competition for palivizumab
Antibody products commonly have long patent “evergreening” timelines across overlapping claims. So the first patent to expire may not be the one that matters most commercially, and launch timing can still depend on:
- Remaining patents covering the product or use
- Litigation or patent disputes
- Regulatory exclusivity or data-protection periods (where applicable)
Are there regional differences (US vs EU vs other countries) in how patent loss affects access?
Yes. Patent rights are territorial, and approval pathways can differ across regions. Even if a patent expires in one country, a company may still be able to enforce other patents in another country, or use different regulatory and pricing dynamics that affect when patients actually see alternative products.
What you can check to pin down the “loss of patent” date for palivizumab in your country
To determine the true practical expiry timeline, the key is to look up the specific patent estates and regulatory listings for the jurisdiction you care about. Typical places to check include:
- Patent registries and court/litigation records for palivizumab
- Regulatory “patent listing” databases used to manage biologic competition approvals
- The product’s regulatory label and indication-specific patent coverage (because launch may be indication-dependent)
If you tell me your country and whether you mean “US patent” or “biologics market entry,” I can give a precise timeline
Patent expiry timelines depend heavily on jurisdiction and on what you mean by “loss of patent” (earliest patent expiry vs. last blocking patent vs. when a biosimilar can launch for a specific indication). If you share:
1) country (e.g., US, UK, EU member state, Canada), and
2) whether you mean “first patent expired” or “when biosimilars can launch,”
I can narrow it to the relevant patent/regulatory framework and dates.